Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. develops and licenses gene-edited plant traits for seed companies rather than selling seed directly. Its proprietary high-throughput gene-editing technologies, including the Rapid Trait Development System™, are used to create productivity traits for major row crops that address yield, weed, disease, insect, nutrient-use and climate-related farming challenges.
Company news commonly covers rice herbicide-tolerance and weed-management traits, seed-company and research partnerships, sustainable ingredients work, regulatory developments for precision breeding, financial results, board composition, shareholder voting matters and capital-structure actions. Updates also describe how Cibus seeks royalty revenue from licensed traits included in customers' seed products.
Cibus (Nasdaq: CBUS) announced a leadership transition under its succession plan. Board member Craig Wichner becomes Chief Executive Officer, while Peter Beetham continues as President and Chief Operating Officer after serving as Interim CEO.
Both Wichner and Beetham resigned from the Board. According to Cibus, Beetham helped raise over $62 million in new investment and advance initial commercialization targets. Wichner, founder of Farmland LP, brings experience overseeing more than $350 million in farmland assets and 19,000 acres.
Cibus (Nasdaq: CBUS) reported first quarter 2026 results and a business update. Cash was $30.3 million at March 31, 2026, with runway expected into late Q1 2027. Net loss was $21.2 million versus $49.4 million a year earlier.
R&D expense fell to $8.7 million and SG&A to $5.1 million, reflecting cost reductions. The company advanced its Rice herbicide tolerance program toward a targeted 2027 Latin America launch, expanded Sustainable Ingredients activities, and raised about $37.3 million gross through two 2026 equity offerings.
Cibus (Nasdaq: CBUS) announced transfer of gene-edited herbicide tolerance materials in rice to partner Interoc to enable testing and production ahead of a planned Latin American seed launch.
The move represents a stated milestone toward commercializing Cibus-developed traits using its Rapid Trait Development System and continuing deliveries to partners over the coming year.
Cibus (Nasdaq: CBUS) will report first quarter 2026 financial results on Thursday, May 14, 2026 after the market close. Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss results and company updates.
Participants may join by phone using the conference ID CIBUS or 24287; a replay and archived webcast will be available through May 28, 2026, and for 90 days online.
Cibus (Nasdaq: CBUS) announced the election of Thomas Urban to its Board of Directors on April 15, 2026. Mr. Urban brings agribusiness scaling, M&A and executive experience from roles at Agribusiness Advisors, CellFor, Pioneer Hi-Bred and Goldman Sachs. He will support Cibus's commercialization and strategic planning.
Cibus (Nasdaq: CBUS) priced an underwritten offering of 6,976,744 Class A shares at $2.15 per share on March 26, 2026, with a 30-day underwriter option for an additional 1,046,511 shares.
Gross proceeds are approximately $15.0 million (or $17.2 million if the option is exercised). The offering is expected to close March 27, 2026. Net proceeds are intended for working capital and to fund development of weed management traits in rice.
Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of Class A common stock and pre-funded warrants on March 25, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered. Net proceeds are intended for working capital and to fund development of weed management traits in rice. The securities will be offered from an effective Form S-3 shelf registration (File No. 333-273062) and a prospectus supplement will be filed with the SEC. The Offering is subject to market and other conditions and may not be completed.
Cibus (Nasdaq: CBUS) reported Q4 2025 results and a business update highlighting Rice program progress, regulatory momentum, and commercialization milestones. Cash was $9.9 million at Dec 31, 2025, and the company raised $22.3 million gross in January 2026.
Key operational notes: targeted Rice launches in LATAM (2027) and USA (2028), first Sustainable Ingredients customer payment in Q4 2025, cost reductions, a $9.1 million impairment, and a plan to reduce net cash usage to about $30 million in 2026.
Cibus (Nasdaq: CBUS) will report fourth quarter 2025 financial results on Tuesday, March 17, 2026 after the market close. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Dial-in numbers, conference ID, replay details, and a live webcast with slides will be available on the company's Investor Events page; an archived webcast will remain available for 90 days.
Cibus (Nasdaq: CBUS) is partnering with the John Innes Centre and other academic and industry collaborators on the UK Government–funded LLS-ERASED precision breeding project to develop durable resistance to Light Leaf Spot in oilseed rape using its Rapid Trait Development System™.
The initiative targets a disease that caused an estimated £300m in grower losses in 2022 and is supported by Defra’s Farming Innovation Programme and at least £21.5m in new funding across 15 projects, aiming to bring precision-bred varieties to UK growers.